Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

Nirmatrelvir is a protease inhibitor that stops the SARS-CoV-2 virus from replicating while ritonavir boosts the activity of ...

People who took Pfizer’s antiviral treatment Paxlovid shortly after infection saw a 26% lower risk of long Covid compared with those who didn’t, the study said.

There is no proven treatment for long Covid-19, which can cause a range of debilitating symptoms in millions of Americans. Skip to content. Exclusive ...

Also Read: Pfizer's Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study The study involved patients aged 25 to 55 who were infected with SARS-CoV ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does ...

Biopharmaceutical company Pfizer will manufacture materials for the antiviral drug Paxlovid in Kalamazoo, Mich., after a $120 million investment for the treatment's first stateside factory.

Earnings Results Pfizer sticks to 2025 profit view as it shrugs off plunging Paxlovid sales for COVID Drug giant’s revenue misses analysts’ estimate as company faces an ‘uncertain and ...

U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus.

Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth in other drugs and product categories. The drugmaker posted a profit of ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects.

Pfizer will provide up to 6 million courses of its antiviral COVID-19 treatment, Paxlovid, for the Global Fund, the pharmaceutical company said Sept. 22.